June 2019

ELRON - INVESTOR PRESENTATION

This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase itssecurities and the presentation does not constitute an invitation to receive such offers, and nothing said therein constitutes a“public offering”, as defined in the Israel Securities Law, 5728-1968.Some of the data in Slide 17 of this presentation that refer to the Company’s share in holdings (in the group companies presentedtherein) based on the value of the last financing round were first included in the presentations the Company makes public after itslast annual reports were issued.Elron may make improvements and/or changes in the features or content presented herein at any time. Elron shall not be liable forany loss, claim, liability or damage of any kind resulting from the investor's reliance on or reference to any detail, fact or opinionpresented herein.The presentation is not intended to provide a comprehensive description of Elron's activities, and Elron urges investors to considerthe information presented herein in conjunction with its public filings including its annual and other periodic reports.Nothing in this presentation should be considered "investment advice", as defined in the Israel Regulation of Investment Advice,Investment Marketing and Portfolio Management Law, 5755-1995.Certain statements made over the course of this presentation may be forward-looking in nature, as defined in Section 32A of theIsrael Securities Law, 5728-1968. Such forward-looking statements involve known and unknown risks, uncertainties, forecasts,assessments, estimates or other information, which relates to a future event or matter whose occurrence is not certain and whichis not within the sole control of Elron, and other factors which may cause the actual results, performance and achievements ofElron to be materially different from any future results, performance and achievements implied by such forward-lookingstatements. These forward looking statements are not proved facts and are based on Elron's subjective assessments which rely onanalysis of general information, public publications, researches and reviews, which do not include any liability as to theaccurateness or completeness of the information contained there and their accurateness hasn't been examined by Elron. Therealization of these forward looking statements will be affected by factors that cannot be assessed in advance and which are notwithin the control of Elron. Elron assumes no obligation to update the information in this presentation and disclaims any obligationto publicly update or revise any such forward-looking statements to reflect any change in its expectations or in events, conditions,or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ fromthose set forth in the forward-looking statements.These estimates, in whole or in part, may not materialize, or may materialize in a manner materially different than expected. Theprincipal factors that may affect this are developments in Elron’s and its group companies’ fields of operation; failure to meet goals;inability to realize technologies; delays or malfunctions in development or manufacture; inability to obtain financing; modificationsin technologies; modifications in work plan, goals and/or strategy; failure or delay in recruiting patients for clinical trials; interimanalysis results; clinical trial results and analysis thereof, which may alter their implication on the regulatory pathways to bepursued for marketing and reimbursement approval of products around the world as well as the actual filing of marketing andreimbursement approval applications; feedback from the medical and scientific community; failure to obtain regulatory approvals;guidance and determinations by regulatory and insurance authorities; or if any risk associated with Elron and its group companiesand the course of product development, clinical trials and their results, data analysis and/or regulatory filings occurs.All amounts are fully attributed to Elron and RDC unless specified otherwise.

COMMENTS

2

1960sDefenseElbit

1970sMedical Imaging

Elscint

1980sSemiconductorsOrbotech | Zoran

1990sCommunications

Netvision | Partner

2000sMulti-strategyGiven Imaging

2010sMedical Devices

Medingo

2020sCyber/IT

BUILDING VALUEIN VENTURE CAPITAL INVESTMENTS

3

Experienced team leading the company over the last decade

10 exits totaling $1.5b,

including proceeds in excess of $500m for Elron and RDC

Long-standing focus in the medical device field

$140mcumulative

dividends since 2012

A portfolio of companies in which

we invested $185m

Successful entry into the cyber/IT

space

BUILDING VALUE IN VENTURE CAPITAL INVESTMENTS

4

BALANCED MATURITY BETWEEN INITIAL R&D STAGE START-UPS THROUGH COMPANIES IN ADVANCED STAGES

MEDICAL DEVICESElron’s field of focus in the last decade

Current portfolio:

6 companies, in which a

total of $390m was

invested

~$150mby Elron

& RDC

4 exits

in the last decade generating $466m in

proceeds for Elron & RDC, reflecting a 2.6x multiple on investment

NEW VERTICAL IN THE LAST 3 YEARS

Current portfolio:

11 companies, in which a

total of $122m was

invested

~$35mby Elron

& RDC

2 exits

in the last 2 years generating $35m in

proceeds for Elron & RDC, reflecting a 3.25x multiple on investment, in an avg. of ~3 years

CYBER/ITDeveloping the field for the next decade

TEAMWORK

5

An experienced team which led 10 exits, dozens of investments, and follow-on financings totaling hundreds of millions of $s over the last decade

ZOHAR ROZENBERGVP Cyber Investments

Col. Ret. Headed the IDF’s Cyber Division in the Intelligence Corp 8200 unit. Established Elron’s cyber portfolio and successfully led the investment and exit of Secdo in 2018. Has been with Elron since 2016.

ZVIKA SLOVINVP Medical Devices

Broad experience in the medical device space as an entrepreneur and investor. Led Elron’s investment in Medingowhich was successfully sold to Roche in 2010, and the investment and sale of Sync-Rx and Kyma. Has been with Elron since 2008.

YARON ELADCFO

Extensive finance experience. Established and manages Elron’s portfolio of IT investments. Led Elron’s investment in Cloudyn which was successfully sold to Microsoft in 2017, and the sale of Jordan Valley and Safend. Has been with Elron since 2007.

ARI BRONSHTEINCEO

Extensive experience in managing and investing in hi-tech companies. Served as a director in several large companies, including CellCom, Hadera Paper, Maxima, and Given Imaging until its sale to Covidien in 2014. Has been with Elron since 2009.

EXITS AT A VALUE OF $1.5B

6

Sold to ROCHE

May 2010

July 2017

Sold to MICROSOFT

Apr. 2018

Sold to PALO ALTO NETWORKS

Oct. 2015

Sold to BRUKER

Sept. 2015

Sold to ZOLL

Nov. 2012

Sold to VOLCANO

Nov. 2011

Sold to ALVARION

Feb. 2014

Acquired byCOVIDIEN

Sept. 2011

Sold to WAVE SYSTEMS CORP

June 2010

Sold to ENABLENCE

Including RDC

Our share in proceeds

$550M

AT THE PIVOT OF OUR ACTIVITY

7

CARTIHEALImplant for cartilage and bone

regeneration in load-bearing joints

Total investment

in company:

$51m

$17m(29%)by Elron

FOUNDED: 2009OUR FIRST INVESTMENT: 2012

MAIN PARTNERS: Johnson & Johnson, Accelmed, aMoon, Bioventus

BRAINSGATEElectrical stimulation-based treatment

for ischemic stroke

Total investment

in company:

$97m

$29m(30%)by Elron

FOUNDED: 2000OUR FIRST INVESTMENT: 2005

MAIN PARTNERS:Johnson & Johnson, Medtronic, Boston Scientific, Pitango,Cipio Partners

OPENLEGACYAutomated API integration platform that speeds digital transformation

Total investment

in company:

$37.4m

$8.2m(29%)by RDC

FOUNDED: 2013OUR FIRST INVESTMENT: 2014

MAIN PARTNERS:CommerzBank, Cardiff/Cathay, OG Tech, Leumi Partners, Prytek, Silverhorn

12 months post-op6 weeks post-op3 weeks post-op

8This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.CartiHeal’s system is an investigational device in the U.S., not approved for marketing there.

Cartilage injuries affect millions of patients worldwide. The need for a simple, fast, and off-the shelf solution to restore cartilage is an unmet challenge facing medicine today.

CARTILAGE & BONE REGENERATION IN JOINTS SUCH AS THE KNEE

>400 patients were treated to date with the implant in a series of clinical trials

CE mark in hand with a broad indication allowing for sales in Europe

In Sep. 2017 a pivotal clinical trial was initiated for FDA marketing approval of the implant in the treatment of traumatic and osteoarthritic defects in the knee: ~190 patients enrolled to date

IN THE NEXT YEAR: After 250 patients are enrolled, an interim analysis of the trial’s results will take place

The annual number of new ischemic strokes in the USA is approximately700,000. The current treatment for stroke is very limited.

ELECTRICAL STIMULATION-BASED TREATMENT FOR ISCHEMIC STROKE

In Mar. 2018 the company completed the largest stroke trial ever done: 1,000 patients, treated on average 19 hours after stroke onset

MECHANICAL THROMBECTOMY:clot removal or aspiration with a catheter

~5% of stroke patients undergo the procedure

IN THE NEXT YEAR:The company intends to submit an application for FDA marketing approval

9

Trial results among cortical stroke patients (50% of the trial population*) demonstrated that SPG stimulation:

reduced disability

reduced the no. of dependent pts. by ~1/3 compared with the control group

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.BrainsGate’s system is an investigational device, not approved for marketing. * BrainsGate estimates that ~25% of ischemic strokes are cortical.

tPAclot-busting drug

~7% of stroke patients receive tPA

In May ‘19, the FDA trial results were published in the scientific journal The Lancet

10ImpACT-24A: Randomized clinical trial that enrolled 300 patients during 2009-2011ImpACT-24B: Randomized clinical trial that enrolled 1,000 patients during 2011-2018

BRAINSGATE’S FDA TRIAL RESULTS

PROFILE The longest clinically tested treatment window – on average, patients were treated 19 hrs after stroke onset

Performed by MDs (mostly neurologists)

EFFICACY Large effect size (9.7%) among cortical stroke patients, marginally missed statistical significance (p=0.0257)

Pooled analysis of ImpACT-24A & B showed a statistically significant (p=0.005) and clinically relevant benefit among cortical stroke patients

Neutral effect in general trial population

SAFETY SPG stimulation was safe across all patient groups

MODE OF ACTION

A strong dose-response relationship between stimulation level and patient outcomes was revealed (p<0.001)

ImpACT-24B: SPG stimulation started within 24 hours reduced disability in a broad category of cortical stroke patients (50% of the trial population)

PARTNERS:

11This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.

FROM LEGACY SYSTEM TO APPLICATION IN RECORD SPEED

Over 20 customers worldwide, including 1st-tier insurance & banking corps

Team of 100 employees, in 8 locations worldwide

The co’s first multi-million-$ transaction with a global banking customer (money transfer API production) demonstrated:

• API performance: 5x faster than existing solution

• >75% reduction in labor cost (20 vs. 120 FTEs)

• Multiple middleware products bypassed ($mn savings)

Raised $30m in financing round from leading strategic investors

IN THE NEXT YEAR:Leverage latest financing round to accelerate global sales

CYBER/IT

THE NEXT DECADE: CYBER & IT

13

ZOHAR ROZENBERGVP Cyber InvestmentsOver 20 years of experience; previously Head of the IDF's Cyber Department; joined Elron in 2016 and established its cyber activities

YARON ELADCFOLeads the IT field; led the investment in Cloudyn which was successfully exited in 2017

LEADERSHIP INVESTMENT

$45mA total of 13 investments

to date

$60mbased on last

financing round in our 11

portfolio co’s

$35mproceeds

from 2 exits

RAFAEL (through RDC, a joint venture)Vast experience in technological projects, extensive knowledge in the cyber and IT spaces, well-established practice of serving as a design partner / beta site for group companies, and often as their first major customer

RAFAEL

CYBER & IT –GROWTH CATALYST IN THE NEXT DECADE

14

Seed Round A Round B

Exit

Exit

TOP HEADLINES ON OUR CYBER/IT COMPANIES

15

INVESTMENT PARTNERS

16

Holdings in companies 1Book value at Mar. 31, 2019 ($m)

Our holdings based on valuation of last financing round 2 ($m)

Medical:

BrainsGate (27%) 1.6

CartiHeal (27%) 3.0

Pocared (55%) 8.8 35.8

Other medical companies 12.2 21.3

Total Medical Holdings 25.6 107.1

Total Cyber/IT Holdings 10.0 37.7

Others 5.8 6.5

Total Holdings 41.4 151.3

Contingent consideration and proceeds in escrow from sale of companies

2.3 2.3

Liquid resources (cash and marketable debentures) (as of May 31, 2019)

32.2 32.2

TOTAL 75.9 185.8

Price per share on TASE (in $) (as of June 3, 2019) $1.66

Elron’s market value (as of June 3, 2019) 49.4

~$185M INVESTED IN COMPANIES, ~$35M LIQUIDITY BALANCE, ~$50 MARKET CAP, NO DEBT

17

1 Includes Elron’s direct holdings and its effective indirect holdings through RDC. Includes investments made after Mar. 31, 2019. Includes Elron’s balance and 50.1% of RDC’s balance.2 The amount includes: A) $96.6m calculated based on the “post-money” valuation of the last financing round in the companies multiplied by our fully diluted holding percentage. It is clarified that these are financing rounds that were carried out in different companies at different dates, and since which, in some cases, significant time has passed. In some of the financing rounds Elron and/or RDC opted not to participate; B) investments in companies presented at fair value in Elron’s financial statements totaling $18.9m (mainly Notal Vision and Aqwise); C) $35.8m attributed to Pocared based on a valuation determined with the assistance of an external appraiser as of Dec. 31, 2018 and which is included in Elron’s periodic report for 2018. 3 The above financial data do not represent a valuation, investment advice, or a financial opinion of any kind.

SUMMARY

18

10 EXITSin recent years

~$220MTotal cash balance & investments in existing companies

IN THE NEXT YEARValue-building events in pivotal companies

This slide contains forward-looking information as defined in Section 32A of the Israel Securities Law, 5728-1968. See Slide 2 of this presentation.

MATURE PORTFOLIO OF COMPANIES

EXPERIENCED TEAMleading the company over the last decade

INVESTMENT OPPORTUNITY IN A PUBLIC COMPANY IN THE VC SPACE, PROVIDING THE WIDER PUBLIC WITH ACCESS TO PRIVATE START-UPS

THANK YOU.elron.com

OUR MEDICAL DEVICE COMPANIES

20

POCARED

Rapid and automated microbiology laboratory system

Our investment:

$83m

71%by Elron & RDC

CARTIHEAL

Implant for cartilage and bone regeneration in load-bearing joints

Our investment:

$17m

29%

BRAINSGATE

Electrical stimulation-based treatment for ischemic stroke Our investment:

$29m

30%

NITINOTES

Minimally invasive endoscopic device for treatment of obesity Our investment:

$3m

31%

CORAMAZE

Transcatheter mitral valve repair system

Our investment:

€5.2m

36%

NOTAL VISION

Remote monitoring of patients with age-related macular degeneration Our investment:

$13.5m

14%

OUR CYBER/IT COMPANIES

SIXGILL

Cyber intelligence platform that automatically & covertly analyzes the dark web

22%

Our investment:

$3.5m

OPENLEGACY

Automated API integration platform that speeds digital transformation Our investment:

$8.2m

29%by RDC

CYNERIO

Protecting the connected medical device ecosystem from cyber threats

Our investment:

$2.3m

24%by RDC

IRONSCALES

Automated phishing prevention, detection & response platform

Our Investment:

$2.5m

24%by RDC

SECUREDTOUCH

Behavioral biometrics-based user authentication for mobile apps Our investment:

$4.5m

28%by RDC

KINDITE

Encryption platform that makes the cloud blind to data & encryption keys Our investment:

$2.5m

28%by RDC

OZCODE

Debugging-as-a-Service (DaaS) that cuts debugging time to minutes Our investment:

$2.5m

27%by RDC

SAYATA

Automated, AI-based cyber risk assessment solution for the insurance industry

Our investment:

$2.5m

21%by RDC

KZEN

Crypto wallet that doesn’t compromise between security and user experience

Our investment:

$0.9m

8%

ALCIDE

Universal security and management platform for hybrid data centers Our investment:

$3.9m

26%